If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
Supply and ordering
Ask sales about Bronchogen availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
Bronchogen is a Khavinson-class short-peptide bioregulator with the sequence Ala-Glu-Asp-Leu (AEDL), targeting respiratory-tissue regulatory pathways within the broader Khavinson bioregulator framework. The molecule was developed at the St. Petersburg Institute of Bioregulation and Gerontology as the respiratory-tissue member of the Khavinson short-peptide family, alongside Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), Cardiogen (cardiovascular), and others. The shared hypothesis is that short tissue-specific peptide fragments isolated from animal tissues act as endogenous bioregulators of cell-cycle and gene-expression programs in their target tissues; Bronchogen specifically is positioned in the Russian-school research literature as a regulatory peptide for bronchial epithelium and respiratory-tissue maintenance. PeptideXpo supplies Bronchogen as a lyophilized 20 mg vial to a ≥99.0% HPLC purity specification. CAS is not consistently registered across suppliers for the Khavinson bioregulator class, so identity is established via mass-spec confirmation of the AEDL tetrapeptide on every batch COA, with sequence verification by LC-MS/MS available on request, particularly important because the four members of the Khavinson tetrapeptide family (AEDG / AEDL / AEDP / KED) are close in mass and require explicit sequencing to disambiguate.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COABronchogen 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Khavinson bioregulator (Russian scientific lineage); CAS commonly not registered. Confirm AEDL sequence and identity per batch COA, disambiguation from sibling tetrapeptides (AEDG / AEDP / KED) in the family is essential since the masses are close.
Selected literature
Frequently asked questions
The Khavinson tetrapeptide family shares an Ala-Glu-Asp tripeptide core (AED-) and differs in the fourth C-terminal residue. Start with the COA matched to the offered Bronchogen lot and review the identity method recorded there. If the buyer's written procedure requires sequence-level evidence, agree the LC-MS/MS or other method, acceptance rule, reporting, timing, and cost with sales before quotation; PeptideXpo does not require an automatic new-supplier retest.
Khavinson-school publications on Bronchogen focus on respiratory-epithelium gene-expression effects in animal models of chronic bronchopulmonary disease and aging-related respiratory decline. The reported readouts include modulation of bronchial epithelial cell proliferation markers, antioxidant-enzyme expression in respiratory tissue, and improvements in pulmonary function metrics in aged-rat models. As with the rest of the Khavinson framework, the evidence base is concentrated in Russian-language journals and translated proceedings from the St. Petersburg Institute of Bioregulation and Gerontology, Western peer-reviewed coverage is limited and the mechanism-of-action data has not been independently replicated outside the Khavinson research lineage at the rigor level Western evidence-based-medicine frameworks expect. Buyers working with Bronchogen should reference the Khavinson primary literature for protocol design and treat the molecule as an investigational research tool.
Published Khavinson-school Bronchogen protocols use both intranasal and intramuscular administration routes. The intranasal route is the more commonly used in respiratory-focused research because direct delivery to the airway epithelium maximizes tissue exposure at the target organ. The intramuscular route produces systemic exposure that is appropriate for studies examining whole-organism effects rather than direct airway-tissue interaction. Working dilutions for intranasal preparation should use isotonic saline as the vehicle with neutral pH (5.5-7.0); benzalkonium chloride and similar quaternary-ammonium preservatives should be avoided in intranasal peptide formulations because they interact with short peptide sequences.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Khavinson cardiovascular short-peptide bioregulator
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
3-mer
Khavinson neuroprotective tripeptide (Glu-Asp-Arg, EDR)
